Legend Biotech is a global clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of transformative cell therapies for the treatment of cancer. Headquartered in Somerset, New Jersey, the company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, with a lead product that has demonstrated significant clinical activity in patients with relapsed or refractory multiple myeloma. Through its proprietary technologies, Legend Biotech seeks to harness the power of the immune system to address some of the most challenging hematologic malignancies.
Founded in 2014 as a spin-out from WuXi AppTec’s cell therapy platform, Legend Biotech has rapidly advanced its pipeline from research to approval. Its flagship therapy combines a novel CAR construct and a streamlined manufacturing process aimed at reducing production time and improving patient access. In partnership with a leading global pharmaceutical company, the company has achieved regulatory approvals in multiple regions, enabling commercial launches in North America, Europe, and parts of Asia.
Legend Biotech operates a vertically integrated business model, encompassing research laboratories, process development centers and commercial manufacturing facilities. This end-to-end infrastructure allows close coordination between discovery scientists, clinical teams and manufacturing experts. The company continues to expand its pipeline beyond multiple myeloma, with early‐stage programs targeting other hematologic and solid tumors. It also explores allogeneic (“off‐the‐shelf”) approaches to broaden patient access and streamline treatment delivery.
Under the leadership of President and Chief Executive Officer Ying Huang and Chief Medical Officer – Oncology Research & Development Sean Moran, Legend Biotech has built a multidisciplinary management team with deep experience in cell therapy, oncology drug development and global commercial strategy. The company contributes to scientific knowledge through collaborations with academic centers and patient advocacy groups, while maintaining a robust intellectual property portfolio. With an eye toward future growth, Legend Biotech continues to invest in next-generation technologies and expand its global footprint to serve patients in need of innovative cancer treatments.
AI Generated. May Contain Errors.
Free LEGN Stock Alerts